Erasca (ERAS) is under pressure after a securities class action lawsuit accused the company of making false and misleading statements about ERAS-0015, including concerns related to patents, trade secrets, and preclinical data.

Despite the legal overhang around ERAS-0015, Erasca’s recent share price momentum has been strong, with a 30 day share price return of 57.48% and a year to date share price return of 425.07%. The 1 year total shareholder return is very large at over 12x, pointing to powerful long term gains that contrast with the recent lawsuit driven volatility.

If you are reassessing biotech risk after Erasca’s legal headlines, this can be a good moment to see what else is moving in healthcare related AI by checking 40 healthcare AI stocks.

Erasca’s pipeline and recent Russell index moves point to a company that investors are treating very differently than a year ago. After such a sharp rally under legal scrutiny, how does the current share price compare with the fundamentals?

Price to Book of 14.9x: Is It Justified?

Erasca’s recent share price surge means investors are now paying a P/B ratio of 14.9x, compared with both its biotech peers and the wider US Biotechs industry.

The P/B ratio compares a company’s share price to its book value per share, which is essentially net assets on the balance sheet. For a clinical stage biotech like Erasca that reports a loss of $277.02 million and makes less than $1 million in revenue, P/B often becomes a primary reference point because earnings and revenue based multiples are not yet meaningful.

At 14.9x, Erasca’s P/B is more than double the peer average of 6.7x and also well above the US Biotechs industry average of 2.8x. That gap suggests the market is putting a premium on Erasca’s pipeline and potential future revenue relative to asset value, even though the company is currently unprofitable, is forecast to remain unprofitable over the next 3 years, and reports a return on equity that is deeply negative as a result of ongoing losses.

Compared with industry norms, this premium P/B multiple points to investors assigning a much richer valuation to Erasca than to many other biotechs with similar sector exposure, despite the company having less than 1 year of cash runway and relying entirely on higher risk external funding sources.

Result: Price-to-book of 14.9x (OVERVALUED).

However, Erasca still faces material risks, including the securities lawsuit around ERAS-0015 and less than 1 year of cash runway, which depends on external funding.

Next Steps

With Erasca attracting both enthusiasm and concern, this is a moment to move quickly, review the data yourself, and weigh the 1 key reward and 4 important warning signs.

Looking for more ideas beyond Erasca?

If Erasca has you rethinking your approach, do not stop here. Broaden your watchlist with a few focused stock ideas that fit different investing priorities.

• Target potential value opportunities by reviewing companies highlighted in the 41 high quality undervalued stocks.
• Strengthen your income focus by scanning businesses featured in the 8 dividend fortresses.
• Prioritize resilience by searching through the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.